BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 12166927)

  • 1. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
    Pellicciari R; Fiorucci S; Camaioni E; Clerici C; Costantino G; Maloney PR; Morelli A; Parks DJ; Willson TM
    J Med Chem; 2002 Aug; 45(17):3569-72. PubMed ID: 12166927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.
    Fiorucci S; Clerici C; Antonelli E; Orlandi S; Goodwin B; Sadeghpour BM; Sabatino G; Russo G; Castellani D; Willson TM; Pruzanski M; Pellicciari R; Morelli A
    J Pharmacol Exp Ther; 2005 May; 313(2):604-12. PubMed ID: 15644430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
    Pellicciari R; Costantino G; Camaioni E; Sadeghpour BM; Entrena A; Willson TM; Fiorucci S; Clerici C; Gioiello A
    J Med Chem; 2004 Aug; 47(18):4559-69. PubMed ID: 15317466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
    Fiorucci S; Rizzo G; Antonelli E; Renga B; Mencarelli A; Riccardi L; Morelli A; Pruzanski M; Pellicciari R
    J Pharmacol Exp Ther; 2005 Oct; 315(1):58-68. PubMed ID: 15980055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in the ligands and their complex structures of farnesoid X receptor].
    Li WH; Fu J; Zheng MY; Liu GX; Tang Y
    Yao Xue Xue Bao; 2012 Jun; 47(6):704-15. PubMed ID: 22919716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T0901317 is a dual LXR/FXR agonist.
    Houck KA; Borchert KM; Hepler CD; Thomas JS; Bramlett KS; Michael LF; Burris TP
    Mol Genet Metab; 2004; 83(1-2):184-7. PubMed ID: 15464433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR).
    Yu D; Mattern DL; Forman BM
    Steroids; 2012 Nov; 77(13):1335-8. PubMed ID: 22999992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The farnesoid X receptor: a novel drug target?
    Claudel T; Sturm E; Kuipers F; Staels B
    Expert Opin Investig Drugs; 2004 Sep; 13(9):1135-48. PubMed ID: 15330745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
    Li YT; Swales KE; Thomas GJ; Warner TD; Bishop-Bailey D
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2606-11. PubMed ID: 18029909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).
    Costantino G; Macchiarulo A; Entrena-Guadix A; Camaioni E; Pellicciari R
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1865-8. PubMed ID: 12749886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
    Pellicciari R; Gioiello A; Costantino G; Sadeghpour BM; Rizzo G; Meyer U; Parks DJ; Entrena-Guadix A; Fiorucci S
    J Med Chem; 2006 Jul; 49(14):4208-15. PubMed ID: 16821780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation.
    Fujino T; Une M; Imanaka T; Inoue K; Nishimaki-Mogami T
    J Lipid Res; 2004 Jan; 45(1):132-8. PubMed ID: 13130122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.
    Fiorucci S; Antonelli E; Rizzo G; Renga B; Mencarelli A; Riccardi L; Orlandi S; Pellicciari R; Morelli A
    Gastroenterology; 2004 Nov; 127(5):1497-512. PubMed ID: 15521018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.
    Huang H; Yu Y; Gao Z; Zhang Y; Li C; Xu X; Jin H; Yan W; Ma R; Zhu J; Shen X; Jiang H; Chen L; Li J
    J Med Chem; 2012 Aug; 55(16):7037-53. PubMed ID: 22862148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
    Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
    Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.
    Akwabi-Ameyaw A; Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Jones SA; Kaldor I; Liu Y; Madauss KP; Marr HB; McFadyen RB; Miller AB; Navas F; Parks DJ; Spearing PK; Todd D; Williams SP; Wisely GB
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4339-43. PubMed ID: 18621523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
    Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A
    Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ileum-liver Farnesoid X Receptor signaling axis mediates the compensatory mechanism of 17α-ethynylestradiol-induced cholestasis via increasing hepatic biosynthesis of chenodeoxycholic acids in rats.
    Zhang F; Xi L; Duan Y; Qin H; Wei M; Wu Y; Li B; Zhou Y; Wu X
    Eur J Pharm Sci; 2018 Oct; 123():404-415. PubMed ID: 30077711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.
    Sepe V; Ummarino R; D'Auria MV; Chini MG; Bifulco G; Renga B; D'Amore C; Debitus C; Fiorucci S; Zampella A
    J Med Chem; 2012 Jan; 55(1):84-93. PubMed ID: 22126372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.